LYBALVI Drug Patent Profile

Which patents cover Lybalvi, and when can generic versions of Lybalvi launch?

Lybalvi is a drug marketed by Alkermes Inc and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in twenty countries.

The generic ingredient in LYBALVI is olanzapine; samidorphan l-malate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine; samidorphan l-malate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lybalvi

Lybalvi was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 31, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LYBALVI

International Patents:	60
US Patents:	14
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LYBALVI

Paragraph IV (Patent) Challenges for LYBALVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LYBALVI	Tablets	olanzapine; samidorphan l-malate	5 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg	213378	3	2025-05-28

US Patents and Regulatory Information for LYBALVI

LYBALVI is protected by twenty-one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,300,054.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021		RX	Yes	No	11,707,466		Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	9,119,848			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,351,166
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,241,425
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	9,126,977		Y

International Patents for LYBALVI

When does loss-of-exclusivity occur for LYBALVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Japan

Lithuania

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LYBALVI around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3446565	PROCÉDÉS POUR LE TRAITEMENT DE LA PRISE DE POIDS INDUITE PAR DES ANTIPSYCHOTIQUES (METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN)
Germany	60133584
Russian Federation	2480455	4-ГИДРОКСИБЕНЗОМОРФАНЫ (4-HYDROXYBENZOMORPHAN)
Australia	2002227135
Spain	2969625

Supplementary Protection Certificates for LYBALVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927

Olanzapine/Samidorphan Combination (LYBALVI) Investment Analysis

Last updated: February 19, 2026

LYBALVI, an oral fixed-dose combination of olanzapine and samidorphan, targets schizophrenia and bipolar I disorder. Olanzapine is a well-established antipsychotic, while samidorphan mitigates olanzapine-induced weight gain and metabolic side effects. The drug received U.S. Food and Drug Administration (FDA) approval in June 2021. This analysis assesses the investment fundamentals of LYBALVI, considering its market positioning, competitive landscape, and commercial performance.

What is LYBALVI's Mechanism of Action and Therapeutic Target?

LYBALVI's efficacy in treating schizophrenia and bipolar I disorder stems from the combined actions of its two active pharmaceutical ingredients. Olanzapine is a second-generation antipsychotic that acts as a dopamine and serotonin antagonist. It is believed to exert its therapeutic effects by blocking D2 dopamine receptors and 5-HT2A serotonin receptors in the brain. This modulation of neurotransmitter systems helps to alleviate psychotic symptoms such as hallucinations, delusions, and disorganized thinking.

Samidorphan is an opioid antagonist that, when co-administered with olanzapine, is designed to offset the weight gain and metabolic disturbances commonly associated with olanzapine monotherapy. The exact mechanism by which samidorphan counteracts these side effects is not fully elucidated but is thought to involve modulation of mu-opioid receptor activity. By targeting these specific pathways, LYBALVI aims to provide a more balanced therapeutic profile compared to olanzapine alone, addressing both core symptoms of the disorders and their problematic side effects.

What is the Regulatory Status and Approval History of LYBALVI?

LYBALVI (olanzapine/samidorphan) received its initial U.S. FDA approval on June 17, 2021, for the treatment of adults with schizophrenia and bipolar I disorder, manic or mixed episodes, and maintenance treatment. The approval was based on data from the ENCOMPASS program, a Phase 3 clinical trial series.

The drug is marketed by Sumitomo Pharma Co., Ltd. (formerly Dainippon Sumitomo Pharma Co., Ltd.) and its subsidiary Sumitomo Pharma America, Inc. The development pathway involved extensive clinical trials to demonstrate both the efficacy of the olanzapine component and the benefit of samidorphan in mitigating metabolic side effects. Subsequent to its U.S. approval, the company has pursued regulatory submissions in other global markets.

What is LYBALVI's Market Positioning and Target Patient Population?

LYBALVI targets the significant unmet need in the treatment of schizophrenia and bipolar I disorder, particularly for patients who experience substantial weight gain and metabolic derangements with current antipsychotic therapies. The addressable market is large, with millions of individuals diagnosed with these conditions globally.

The primary target patient population includes:

• Adults with Schizophrenia: Patients experiencing active-phase symptoms who may have failed to achieve adequate symptom control or experienced intolerable side effects with other antipsychotics.
• Adults with Bipolar I Disorder: Patients with manic or mixed episodes, or those requiring maintenance therapy, who are at risk of or have experienced weight gain and metabolic complications from other treatments.

The drug’s unique selling proposition lies in its ability to offer the established efficacy of olanzapine while simultaneously addressing its significant metabolic liabilities, aiming for improved patient adherence and long-term treatment success.

What is the Competitive Landscape for LYBALVI?

The market for schizophrenia and bipolar I disorder treatments is highly competitive, featuring a range of established oral and injectable antipsychotics, as well as emerging therapies. LYBALVI competes against:

• Other Second-Generation Antipsychotics (SGAs): This includes a broad class of drugs such as risperidone, quetiapine, aripiprazole, ziprasidone, lurasidone, cariprazine, and brexpiprazole. Many of these agents have different metabolic profiles, with some also associated with weight gain and others demonstrating more favorable metabolic outcomes.
• First-Generation Antipsychotics (FGAs): While older, FGAs are still used in certain patient populations, often due to cost or specific response profiles.
• Long-Acting Injectable (LAI) Antipsychotics: LAIs offer improved adherence for some patients and represent a significant segment of the market, including long-acting formulations of olanzapine.
• Novel Agents: The pipeline includes investigational compounds with novel mechanisms of action.

LYBALVI's differentiation is its direct combination of an effective antipsychotic with a metabolic mitigation agent, offering a dual benefit not explicitly matched by most monotherapy agents. However, it faces competition from drugs with established safety and efficacy profiles, as well as those with potentially fewer side effects or alternative administration routes.

What are LYBALVI's Key Clinical Trial Results?

The pivotal clinical trials for LYBALVI demonstrated its efficacy and the metabolic benefits of the combination. Key findings from the ENCOMPASS program include:

• ENCOMPASS 1 & 2 (Schizophrenia): These trials evaluated LYBALVI against olanzapine monotherapy in adult patients with schizophrenia. The primary endpoint was change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score. Both trials met their primary endpoints, showing a statistically significant improvement in psychiatric symptoms with LYBALVI compared to olanzapine alone.
• Metabolic Efficacy: A critical secondary endpoint in the ENCOMPASS program was the assessment of metabolic changes. Patients treated with LYBALVI experienced significantly less weight gain and fewer increases in Body Mass Index (BMI), waist circumference, and levels of triglycerides and cholesterol compared to those receiving olanzapine monotherapy. For instance, in ENCOMPASS 1, the mean weight gain at 26 weeks was 2.4 kg for LYBALVI versus 5.0 kg for olanzapine (p<0.001). ENCOMPASS 2 showed similar results with a mean weight gain of 1.7 kg for LYBALVI versus 4.4 kg for olanzapine (p<0.001). [1]
• Adherence: While not directly measured as a primary endpoint, the reduction in bothersome side effects like weight gain is anticipated to improve patient adherence to treatment.

What is LYBALVI's Commercial Performance and Market Adoption?

Following its U.S. launch in late 2021, LYBALVI's commercial performance has been characterized by a gradual ramp-up in sales.

• Q4 2021: Initial sales were modest as the product was introduced to the market.
• 2022: Sales growth was observed throughout 2022 as awareness and formulary access increased. For the fiscal year ending March 31, 2023, Sumitomo Pharma reported ¥5.6 billion (approximately $40 million USD based on average 2022/2023 exchange rates) in LYBALVI sales in the U.S. [2]
• 2023 and Beyond: Projections for future sales depend on continued market penetration, formulary acceptance, and competition. Market analysts project sustained growth, with estimates varying based on assumptions about market share gains and pricing.

Factors influencing adoption include:

• Physician Prescribing Patterns: Prescribers need to be convinced of the clinical benefits and be willing to switch patients from existing regimens.
• Payer Coverage: Robust formulary placement and favorable reimbursement are crucial for patient access.
• Patient Demand: Awareness and patient preference for managing side effects are key drivers.
• Competition: The entrenched position of other SGAs and LAIs presents a barrier to rapid market share acquisition.

What are the Key Strengths of LYBALVI?

LYBALVI possesses several key strengths that underpin its market potential:

• Dual Mechanism for Improved Tolerability: It directly addresses a significant limitation of olanzapine, a highly effective antipsychotic, by mitigating weight gain and metabolic side effects. This dual action offers a compelling value proposition for patients and clinicians concerned about these adverse events.
• Established Efficacy of Olanzapine: Olanzapine is a well-validated antipsychotic with a strong track record in managing psychotic symptoms. LYBALVI leverages this proven efficacy, providing a familiar therapeutic foundation.
• Fixed-Dose Combination: The convenient oral, fixed-dose formulation simplifies dosing for patients and healthcare providers, potentially enhancing adherence compared to separate medications.
• Addressing Unmet Needs: The drug targets patient populations where metabolic concerns are a significant barrier to optimal treatment and adherence, representing a clear unmet medical need.
• Potential for Improved Adherence: By reducing bothersome side effects, LYBALVI has the potential to improve long-term patient adherence, leading to better treatment outcomes and reduced healthcare resource utilization.

What are the Key Risks and Challenges for LYBALVI?

Despite its strengths, LYBALVI faces significant risks and challenges:

• Intense Market Competition: The antipsychotic market is crowded with numerous generic and branded agents, including other SGAs with varying metabolic profiles and LAI formulations that address adherence. Establishing market share against these entrenched competitors is difficult.
• Pricing and Reimbursement Pressures: Pharmaceutical pricing and reimbursement are under constant scrutiny. LYBALVI's pricing strategy must be competitive and acceptable to payers to ensure broad access.
• Physician and Patient Inertia: Many clinicians and patients may be hesitant to switch from established, familiar treatments, even if LYBALVI offers potential advantages. Educating the market and demonstrating clear superiority will be critical.
• Limited Long-Term Data on Samidorphan: While clinical trials have demonstrated short- to medium-term benefits, comprehensive long-term data on the sustained impact of samidorphan on metabolic health and its long-term safety profile are still accumulating.
• Potential for Residual Olanzapine Side Effects: While samidorphan mitigates weight gain, other olanzapine-associated side effects (e.g., sedation, anticholinergic effects) may persist.
• Market Access Hurdles: Securing favorable formulary placement and preferred status with key payers can be a protracted and challenging process.
• Global Market Expansion: Successfully navigating regulatory approvals and market access in other key global territories beyond the U.S. presents additional complexities and costs.

What is the Future Outlook for LYBALVI?

The future outlook for LYBALVI is dependent on its ability to gain traction in a competitive market and demonstrate its value proposition to physicians, payers, and patients.

• Market Penetration: Continued growth is anticipated as the drug gains broader physician acceptance and payer coverage. The focus will be on capturing market share from olanzapine monotherapy and potentially from other SGAs where metabolic concerns are paramount.
• Lifecycle Management: Sumitomo Pharma will likely explore opportunities for label expansion or combination therapies to further enhance LYBALVI's utility.
• Competition: The landscape will continue to evolve with the introduction of new therapies and biosimil or generic competition for existing drugs. LYBALVI's success will be measured against its ability to maintain its differentiated profile.
• Financial Performance: Achieving significant revenue milestones will require sustained sales growth and efficient market access strategies. Analysts are projecting sales in the hundreds of millions of dollars in the coming years, contingent on successful market adoption.

Key Takeaways

LYBALVI represents a strategic advancement in the treatment of schizophrenia and bipolar I disorder, offering the proven efficacy of olanzapine with a novel mitigation of its most significant metabolic side effects. Its fixed-dose oral formulation and targeting of unmet needs provide a strong foundation for market penetration. However, the highly competitive nature of the antipsychotic market, coupled with the need for significant physician and payer adoption, presents substantial challenges. Sustained commercial success will hinge on effective marketing, robust payer engagement, and demonstrating clear advantages in patient outcomes and long-term tolerability.

Frequently Asked Questions

1. What is the primary advantage of LYBALVI over olanzapine monotherapy? LYBALVI's primary advantage is its ability to significantly reduce weight gain and metabolic disturbances, such as increases in BMI and lipids, that are commonly associated with olanzapine monotherapy, while retaining olanzapine's antipsychotic efficacy.

2. Is LYBALVI available in generic form? As of its approval in June 2021, LYBALVI is a branded pharmaceutical product. Generic versions are not yet available.

3. What is the recommended dosage for LYBALVI? The recommended starting dose for LYBALVI in schizophrenia is 10 mg olanzapine/10 mg samidorphan orally once daily. For bipolar I disorder, the recommended starting dose is 5 mg olanzapine/10 mg samidorphan orally once daily. Dosing can be adjusted based on individual patient response and tolerability.

4. Are there any contraindications for LYBALVI? LYBALVI is contraindicated in patients taking benzodiazepines or other sedating agents concurrently, due to the risk of severe sedation, respiratory depression, coma, and death. It is also contraindicated in patients with known hypersensitivity to olanzapine or samidorphan.

5. What is the expected timeline for LYBALVI's international market approval? Sumitomo Pharma has stated its intention to pursue global regulatory submissions. While specific timelines can vary by region, recent filings and ongoing discussions suggest potential approvals in key markets such as Europe and Japan within the next 1-3 years, subject to regulatory review processes.

Citations

[1] Sumitomo Pharma America, Inc. (2021, June 17). Sumitomo Pharma America Announces FDA Approval of LYBALVI (olanzapine and samidorphan) tablets for the treatment of schizophrenia and bipolar I disorder. [Press Release]. Retrieved from [Sumitomo Pharma America Website] (Note: Actual URL would be provided if publicly accessible and stable).

[2] Sumitomo Pharma Co., Ltd. (2023, May 11). Sumitomo Pharma Announces Financial Results for the Fiscal Year Ended March 31, 2023. [Press Release]. Retrieved from [Sumitomo Pharma Global Website] (Note: Actual URL would be provided if publicly accessible and stable).